Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Nov 14, 2025
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the third quarter ended September 30, 2025.
Read more at globenewswire.com
